Every year, over 14 million people worldwide are newly diagnosed with cancer. China ranks first in the world as 4.3 million people newly diagnosed with cancer in 2016. That’s why we created Natural Killer T (NKT) cell therapy as the next generation standard care in cancer patients. We are harnessing the full power of our body’s own immune system by developing NKT cell-based cancer treatment. Our multifunctional NKT cell (mNKT1) has a broad way of activating receptors (e.g. NKG2D) and 100% eliminate many types of solid cancer cells within 12 hours. Our unique media enables us to produce off-the-shelf, ready-to-use mNKT1 cells to treat 1 million cancer patients within 90 days. Unlike Car-T, mNKT1 serves as a universal, heterogeneous cell-based therapy that doesn’t require individualized patient matching. This off-the-shelf approach is also very cost-effective. This next generation NKT cell therapy is our powerful weapon as part of our ambitious goal to win the war on cancer by the year 2020.